NASDAQ$ALDX
Aldeyra Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Aldeyra reported full-year financial results and corporate highlights.
Aldeyra Therapeutics reported its full-year 2022 financial results, highlighting the Priority Review Designation for ADX-2191 and the NDA review for Reproxalap. The company's cash, cash equivalents, and marketable securities totaled $174.3 million as of December 31, 2022, expected to fund operations into the second half of 2024.
- NDA for ADX-2191 received Priority Review Designation for primary vitreoretinal lymphoma treatment with a PDUFA date of June 21, 2023.
- NDA for Reproxalap accepted for review for treating dry eye disease with a PDUFA date of November 23, 2023.
- Positive top-line results were announced from the 12-month safety clinical trial of Reproxalap in dry eye disease.
- Phase 2 clinical trials were initiated for ADX-629 in systemic immune-mediated diseases.
Headline financials
Revenue & EPS history
Aldeyra · Revenue · Quarterly
$0
Forward guidance
Aldeyra anticipates several clinical and regulatory milestones in the near term. The company believes existing cash, cash equivalents, and marketable securities will be sufficient to fund currently projected operating expenses into the second half of 2024.
Tailwinds
- Top-line results from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis are expected in the first half of 2023.
- Top-line results from the Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa are expected in the first half of 2023.
- Top-line results from the Phase 2 Clinical Trial of ADX-629 in Chronic Cough are expected in the first half of 2023.
- Phase 1 clinical trial of orally administered ADX‑246 for the treatment of systemic immune-mediated diseases is expected to initiate in the second half of 2023 or early 2024.
- Phase 1/2 clinical trial of intravitreally injected ADX‑248 for the treatment of geographic atrophy is expected to initiate in the second half of 2023 or early 2024.
Headwinds
- Clinical trial timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors.
- Delay in or failure to obtain regulatory approval of Aldeyra's product candidates.
- Uncertainty as to Aldeyra’s ability to commercialize and obtain reimbursement for Aldeyra's product candidates following regulatory approval.
- The rate and degree of market acceptance of any of Aldeyra's product candidates is uncertain.
- The current and potential future impact of the COVID-19 pandemic on Aldeyra’s business, results of operations, and financial position.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.7%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
47%
24 / 51 earnings
Positive
+22.7%
Q4 2026
Best reaction
-14.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +22.7% | -2.3% | -6.4% | |
| Q3 2025 | -2.5% | +10.2% | -2.3% | |
| Q1 2025 | +0.9% | -3.6% | +72.3% | |
| Q4 2024 | +4.5% | +4.4% | -71.5% | |
| Q3 2024 | +2.2% | -11.9% | -3.3% | |
| Q2 2024 | -10.7% | -12.7% | +46.1% | |
| Q1 2024 | -1.0% | -0.7% | -8.1% | |
| Q4 2023 | -7.9% | -23.5% | +20.1% | |
| Q3 2023 | +7.7% | +24.9% | +36.8% | |
| Q2 2023 | +0.8% | -6.6% | -5.0% | |
| Q1 2023 | +3.8% | +0.8% | +4.6% | |
| Q4 2022 | -2.6% | +6.6% | +34.2% | |
| Q3 2022 | +12.2% | +9.5% | +18.5% | |
| Q2 2022 | +15.4% | +24.0% | +11.2% | |
| Q1 2022 | -7.5% | -10.2% | +4.1% | |
| Q4 2021 | +18.4% | +19.4% | +9.1% | |
| Q3 2021 | +10.4% | +6.9% | -6.8% | |
| Q2 2021 | +11.1% | +8.4% | +4.3% | |
| Q1 2021 | +4.3% | +4.8% | +5.6% | |
| Q4 2020 | +3.6% | -3.1% | -0.3% | |
| Q3 2020 | -1.6% | -1.6% | +5.7% | |
| Q2 2020 | -4.4% | -11.4% | -21.6% | |
| Q1 2020 | -2.7% | +14.3% | +64.8% | |
| Q4 2019 | -10.0% | -27.6% | -15.4% | |
| Q3 2019 | -1.7% | +1.0% | -21.6% | |
| Q2 2019 | -4.2% | -0.7% | -9.4% | |
| Q1 2019 | -2.9% | -7.0% | -14.4% | |
| Q4 2018 | +2.3% | +20.2% | +15.1% | |
| Q3 2018 | -13.1% | -11.1% | -6.2% | |
| Q2 2018 | +8.4% | +5.6% | +10.5% | |
| Q1 2018 | +2.9% | +1.7% | +0.0% | |
| Q4 2017 | -14.1% | -14.7% | -1.8% | |
| Q3 2017 | +2.6% | +4.3% | +19.8% | |
| Q2 2017 | -7.4% | -6.4% | -10.6% | |
| Q1 2017 | +7.6% | +12.7% | +17.7% | |
| Q4 2016 | -2.9% | +1.0% | -15.5% | |
| Q3 2016 | +2.7% | -3.6% | -22.5% | |
| Q2 2016 | +0.3% | -2.8% | -3.8% | |
| Q1 2016 | -3.1% | — | — | |
| Q4 2015 | -1.4% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -5.3% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -3.7% | — | — | |
| Q3 2013 | +5.3% | — | — | |
| Q3 2014 | +5.5% | — | — | |
| Q2 2013 | +15.0% | — | — | |
| Q2 2014 | -6.3% | — | — | |
| Q1 2014 | -4.6% | — | — | |
| Q1 2013 | -4.6% | — | — | |
| Q4 2013 | -4.6% | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro